Teva and Heptares to develop treatments for migraine
25 November 2015 | By Victoria White
The companies have entered an agreement to discover and develop novel, small-molecule CGRP antagonists for the treatment of migraine...
List view / Grid view
News
Scientists use X-ray crystallography to see pneumolysin
24 November 2015 | By Victoria White
Pneumolysin is associated with deadly infections such as bacterial pneumonia, meningitis and septicaemia...
UCL launches gene therapy company Athena Vision
24 November 2015 | By Kate Douetil
UCL has announced the formation of Athena Vision, a biopharmaceutical company focused on developing gene therapies for eye diseases...
LSP and Bristol-Myers Squibb team up for life sciences innovation
24 November 2015 | By Victoria White
The companies have said they will focus is on immuno-oncology, one of the hottest and most dynamic areas in biotechnology...
TSRI scientists reveal potential treatment for dangerous viral infections
23 November 2015 | By Victoria White
Scientists have shown how a previously unknown process works to promote infection in a number of dangerous viruses, including dengue, West Nile and Ebola...
A drug that heals broken bones faster and better
23 November 2015 | By Victoria White
Using bone samples from people undergoing hip replacement surgery, researchers were able to show that a drug that activates the Wnt pathway causes stem cells found within bones to divide and to turn into more bone cells...
£1 billion fund set up to fight malaria and other infectious diseases
23 November 2015 | By Victoria White
The Ross Fund includes £115 million to develop new drugs, diagnostics and insecticides for malaria, TB and other infectious disease resistance...
Evgen expands pipeline with novel compounds
23 November 2015 | By Victoria White
Evgen has said it will use its Sulforadex platform to synthesise and stabilise the newly acquired compounds with a view to taking the most promising into clinical development...
University of Sheffield appoints Cobra to advance growth hormone antagonist
23 November 2015 | By Victoria White
Cobra will be using its cell line development service, maxXpress, to produce the growth hormone antagonist fusion protein...
Cocktail of mutant proteins linked to Huntington’s disease
20 November 2015 | By Victoria White
Researchers have shown that the gene that causes Huntington's diseases makes an unexpected "cocktail" of mutant proteins that build up in regions of the brain that are most affected by the disease...
AstraZeneca invests in its Cambridge lead discovery centre
20 November 2015 | By Victoria White
The company has announced three new partnerships that will deliver a collaborative screening platform, space-age robotics, and sound waves that can move liquids...
Intelligent biogel effective at delivering anti-cancer agents
20 November 2015 | By Victoria White
The technology has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionise treatment for many forms of cancer...
Sanofi and AstraZeneca exchange 210,000 chemical compounds
20 November 2015 | By Victoria White
The compound exchange represents a novel, open innovation model of collaboration between the two companies.
FDA clears first-in-human clinical study for MERS vaccine
19 November 2015 | By Victoria White
GeneOne Life Science and Inovio are co-developing the vaccine and plan to initiate the first human trial of a MERS vaccine before the end of the year...
Presence of protein aggregates as important as form in cell death
19 November 2015 | By Victoria White
Scientists have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue...
